AREG and ovarian cancer: Importantly, it was previously shown that AREG-stimulated cell migration and proliferation were largely blocked by the addition of the metalloprotease inhibitor GM6001 to prevent the processing of membrane-bound AREG precursors into soluble AREG in ovarian cancers [46].